Strategic NHS Partnering Skin Analytics has an established track record with the NHS since 2020, with DERM deployed across 25 primary and secondary care organisations and a strong reputation as the NHS's first and only AI skin cancer pathway. This demonstrates a proven public sector footprint and credibility that sales teams can leverage to expand within NHS networks and explore new regional contracts or extended deployments.

Regulatory and Quality Standing DERM is NICE-recommended and is the only Class III CE marked AI medical device for skin cancer, underscoring high regulatory clearance and clinical trust. This positions Skin Analytics favorably for hospitals and insurers seeking compliant, high-stakes AI solutions, and can be highlighted in pitches to procurement teams prioritising risk reduction and accredited technologies.

Scale and Impact Pathways have processed over 170,000 NHS patients and identified more than 15,500 cancers, with NHS entities able to avoid up to 95% of face-to-face appointments in secondary care. This demonstrates substantial volume, efficiency gains, and cost savings potential, which can be compelling for health systems facing backlogs and capacity constraints.

Strategic Partnerships Recent and ongoing partnerships with Healthdirect Australia, Nordic market entrants via Human Bytes ApS, and collaborations with insurers like Freedom Health and Affidea indicate a growing ecosystem and cross-border expansion. These relationships create opportunities for co-selling, regional pilots, and multi-channel distribution partnerships.

financed Growth A significant Series B raised in 2025 and ongoing funding, along with a sizable revenue range and a clear mission to reduce mortality from skin cancer, signal scalable growth and investment-ready capabilities. This supports conversations with enterprise health networks and private insurers about large-scale deployments and long-term contract opportunities.